SMMT
Summit Therapeutics Inc.
Set alert
16.03 USD -0.17 -1.05%
15.57 Day range 16.43
12.43 52-week range 26.38
- YTD
- -8.35%
- 1 year
- -14.00%
- Open
- 16.03
- Prev close
- 16.20
- Mkt cap
- 12.79B
- Vol
- 3.51M
- Avg vol
- 6.07M
- EPS
- -1.11
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.57
- High
- 16.43
- Forward P/E
- -13.29
- Beta
- -1.52
- Short ratio
- 5.67
- Inst. own
- 17.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 15.98
- 200-d avg
- 16.18
- 1y target
- 30.24
Key statistics
- Market cap
- 12.45B
- Enterprise value
- 12.25B
- Trailing P/E
- 0.00
- Forward P/E
- -13.29
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 19.65
- EPS (TTM)
- -1.11
- Beta
- -1.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -139.68M
- Total cash
- 690.68M
- Total debt
- 20.38M
- Return on equity
- -192.50%
- Shares outstanding
- 797.75M
- Short % of float
- 26.14%
- 50-day average
- 15.98
- 200-day average
- 16.18
Analyst view
Consensus: buy
Buy
Price target (mean) 30.24 +88.7% upside
Now 16.03
- Target (low)
- 11.92
- Target (mean)
- 30.24
- Target (high)
- 43.80
Ratings (0m) 17 11 buy · 6 hold · 0 sell
- Strong buy1
- Buy10
- Hold6
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate -0.20808.
Financials — quick view
SMMT Revenue — quarterly 0
SMMT Net income — quarterly -215.70M
SMMT EPS — quarterly -0.003
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | -0.28063 | — | — | — |
| Jul 23, 2026 | Jun 30, 2026 | -0.27439 | -0.28 | -0.01 | -2.04% |
| Apr 30, 2026 | Mar 31, 2026 | -0.33 | -0.24 | +0.09 | +27.27% |
| Feb 23, 2026 | Dec 31, 2025 | -0.10264 | -0.29 | -0.19 | -182.54% |
| Oct 20, 2025 | Sep 30, 2025 | -0.17577 | -0.31 | -0.13 | -76.37% |
| Aug 11, 2025 | Jun 30, 2025 | -0.09081 | -0.76 | -0.67 | -736.91% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2026 | Barclays | main | Equal-Weight | Equal-Weight |
| Sep 29, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Sep 9, 2026 | Jefferies | up | Hold | Buy |
| Aug 26, 2026 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Aug 25, 2026 | Bernstein | up | Underperform | Market Perform |
About Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- smmttx.com
News
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
- Breakfast News: Science Strikes Back at Cancer
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S
- Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
- Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
- Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
- Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
- Summit Expands Ivonescimab Development Into Biliary Tract Cancer
- Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
- Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
Your note
Sign in to keep a note on SMMT — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 4.10% | 32,786,348 | 511.63M | Jun 29, 2026 |
| FMR, LLC | 1.26% | 10,043,947 | 156.74M | Jun 29, 2026 |
| State Street Corporation | 1.19% | 9,536,796 | 148.82M | Jun 29, 2026 |
| Blackrock Inc. | 1.19% | 9,529,041 | 148.70M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 0.72% | 5,734,484 | 89.49M | Jun 29, 2026 |
| UBS Group AG | 0.65% | 5,233,798 | 81.67M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.46% | 3,707,548 | 57.86M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 0.45% | 3,635,145 | 56.73M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.33% | 2,667,317 | 41.62M | Jun 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.32% | 2,531,231 | 39.50M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.26% | 2,047,862 | 31.96M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.22% | 1,778,361 | 27.75M | Jun 29, 2026 |